Sclerostin Quo Vadis? - Is This a Useful Long-Term Mortality Parameter in Prevalent Hemodialysis Patients?

Background/Aims: Cardiovascular calcification contributes to the increased mortality in hemodialysis patients. Sclerostin was identified as an antianabolic bone factor causing soft tissue calcification. Data on prospective large-scale studies associating sclerostin with mortality in hemodialysis patients are so far inconsistent. Methods: In our multicenter prospective longitudinal study following hemodialysis patients, we assessed the associations of sclerostin and bone remodeling markers with long-term mortality. We evaluated the relationship between circulating sclerostin, Fibroblast growth factor 23 (FGF23) and traditional bone remodeling markers. Sclerostin levels in hemodialysis patients were compared with healthy controls. Results: We enrolled 239 hemodialysis patients with a median follow up of 1461 days. In Cox regression analysis, FGF23 (HR 1.40; 95% CI 1.11-1.76), parathyroid hormone (PTH) (HR 1.80; 95% CI 1.44-2.26) and alkaline phosphatase (AP) (HR 1.50; 95% CI 1.10-2.04) per SD, 25(OH) vitamin D (HR 0.42; 95% CI 0.23-0.76) per natural log but not sclerostin (HR 1.02; 95% CI 0.75-1.38) per SD increase were associated with mortality. FGF23, PTH and AP were negatively associated with sclerostin. Among control and hemodialysis females, sclerostin levels were lower than in men. Conclusion: Higher FGF23, PTH, AP and lower 25(OH) vitamin D but not sclerostin predict long-term mortality. Sclerostin was negatively associated with FGF23, PTH and AP and lower in females than in males. Copyright (C) 2015 S. Karger AG, Basel